NEW YORK & MCLEAN, Va., October 05, 2022--(BUSINESS WIRE)--Massive Bio, a leader in AI-powered cancer clinical trial enrollment, announced a strategic partnership with Perthera.ai, a pioneer in connecting oncologists and patients with biomarker-based therapy options. Perthera.ai’s patented ranked therapy recommendations complement Massive Bio’s screening and analysis to empower more cancer patients to find an appropriate clinical trial.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005225/en/
Less than three percent of cancer patients today are matched and enrolled in a clinical trial. By combining the advanced computational methods and artificial intelligence capabilities of both companies, more physicians and patients will be able to confidently access the benefits of investigational precision oncology treatments from FDA-approved and novel therapies that are specific to patients’ unique molecular and genetic biomarkers. Perthera.ai combines multi-omic testing results (DNA, RNA, IHC and phosphoproteomics) to advise oncologists and their patients and simplify the decision-making process to increase the chance that the best therapy is used the first time.
"We are excited to partner with Massive Bio to leverage the most advanced science and technology to help as many cancer patients as possible," said Albert Kelley, CEO of Perthera.ai. "Increasing access to genomic and multi-omic testing and patient-trial matching solutions is the best way to advance cancer care for all. We believe in collaboration where it can help more patients and by combining forces with Massive Bio, we can improve data acquisition and the accuracy of patient-trial matching."
"Our mission is to create hope and empower cancer patients by helping them find their best treatment options, which often requires access to clinical trials," said Selin Kurnaz, co-founder and CEO of Massive Bio. "By combining Perthera.ai’s focus on biomarker-based algorithms with our AI-powered clinical trial matching platform, we can create more options for patients and physicians to find the best trials. We can also pursue additional innovations together around real-world data, biomarker discovery, and diagnostic and commercial collaborations with industry stakeholders."
Dr. Arturo Loaiza-Bonilla, co-founder and Chief Medical Officer of Massive Bio, added: "We are excited to expand our data sets and leverage our technologies and combined networks to offer more precise treatment paths, which will have an immediate and positive impact to identify more treatment options for more patients."
Perthera.ai is a pioneer in using multi-omic testing results to advise oncologists and patients on treatment options through our Precision Oncology Platform and the Perthera Report that it generates. Perthera.ai collects multi-omic results from any source and uses a patented Precision Oncology Platform to generate ranked therapy options that have been shown to increase survival in patients with pancreatic cancer who use a highly ranked therapy. Perthera.ai aspires to bring its proprietary technology to as many patients with cancer as possible without regard for location or financial resources.
Massive Bio empowers cancer patients to find their best treatment options, providing convenient access and enrollment services for oncology clinical trials worldwide, powered by advanced artificial intelligence. Founded on the belief that all people should have equal access to leading-edge therapies, Massive Bio combines its best-in-class AI platform with expertise in genomics, engineering, and data analytics to remove the many barriers to cancer patient enrollment and participation in clinical trials. Headquartered in New York, Massive Bio is a privately held company that operates in 12 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005225/en/
Massive Bio: Lisa Barbadora, lbarbadora@bigvalley.co, +1 610-420-3413
Perthera.ai: Albert Kelley, akelley@perthera.com or hope@perthera.com
Photo Illustration by Erin O'Flynn/The Daily Beast/GettyA new subvariant of the novel-coronavirus called XBB dramatically announced itself earlier this week, in Singapore. New COVID-19 cases more than doubled in a day, from 4,700 on Monday to 11,700 on Tuesday—and XBB is almost certainly why. The same subvariant just appeared in Hong Kong, too.A highly mutated descendant of the Omicron variant of the SARS-CoV-2 virus that drove a record wave of infections starting around a year ago, XBB is in ma
BQ.1.1's extreme immune evasiveness "sets it up to be the principal driver of the next U.S. wave in the weeks ahead," a leading expert said Friday.
The things to remember about dementia are that it is absolutely horrible for you and everyone around you; it’s a high probability; and when it comes to fighting it or avoiding it you are pretty much on your own. Alzheimer’s disease and related dementias are currently killing 6.5 million people in the United States and devastating the lives of many times that when you count the patients’ friends and family. The National Institutes of Health reckons this number is likely to double in the next four decades.
Heart disease is the leading cause of death in the U.S. among both men and women, accounting for one in every five deaths in the nation. Despite these frightening statistics, many of us still unknowingly put ourselves at heightened risk of heart disease through our health and lifestyle habits. Now, a new study is shedding light on one way we accidentally increase our risk: A common medication used by millions of Americans could put us in danger. Read on to learn which drug could be endangering y
"It's disgusting," said Good Sam nurse Liz Erwin. "They understaffed the ER to the point where it's impossible for them to provide acceptable care."
Two new offshoots that experts say appear to spread easily were estimated to represent 11.4% of U.S. cases by mid-October, according to the CDC.
The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya. Reportedly, Novartis sued HEC and several other generic drugmakers, accusing them of patent infringement, in Delaware federal court after they applied for FDA approval of Gilenya generics. According to a Reuters report, Novartis had asked the justices to suspend a lower court's ruling that lifted a ban on generic versions of Gilenya. Related: Novartis D
Rhinovirus, which typically causes the common cold, is back in a big way. "These viruses are stronger than they have been in years," says one expert.
Dr. Carrie Jose, in her latest health and wellness column, provides three simple tips to protect your knees from arthritis.
The minimum treatment for a snake bite is 10 vials of antivenom and the cost of each vial is in the four digits.
Story at a glance A recent analysis from Better Benefits Guide ranked all 50 states based on their healthcare systems. Massachusetts, California and New York came in at the top three with a decent number of hospitals in each state. The analysis found that Alabama, Arkansas and Delaware have the worst healthcare systems.…
Getting rest days in between workouts is important for recovery
Sometimes the smallest mistakes can impact your health in a major way. Although they might not seem like a big deal at first, simple errors can play havoc on your overall well-being. While we're all guilty of committing some unhealthy habits, there's a few that should always be avoided. Eat This, Not That! Health spoke with Dr. Janice Johnston, MD, Chief Medical Officer&Co-Founder at Redirect Health who shares five things to stop doing now in order to achieve optimal health. Read on—and to ensur
A dearth of research on medical conditions affecting women has led a UCLA researcher to look for insights from the female animal kingdom.
Children’s hospitals in major U.S. cities have been reporting unusually high numbers of sick patients with respiratory illnesses caused by viruses other than the coronavirus. These include respiratory syncytial virus (RSV), enteroviruses (EV) and rhinovirus (RV).
The U.S. Department of Agriculture on Friday proposed sweeping changes in the way chicken and turkey meat is processed that are intended to reduce illnesses from food contamination but could require meat companies to make extensive changes to their operations. Despite decades of efforts to try and reduce illnesses caused by salmonella in food, more than 1 million people are sickened every year and nearly a fourth of those cases come from turkey and chicken meat. As it stands, consumers bear much of the responsibility for avoiding illness from raw poultry by handling it carefully in the kitchen — following the usual advice to not wash raw chicken or turkey (it spreads the bacteria), using separate utensils when preparing meat and cooking to 165 degrees.
Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.
Pfizer (PFE) and partner BioNTech's Omicron BA.4/BA.5-adapted bivalent COVID vaccine exhibits substantial antibody response above pre-booster levels in adults after seven days of dose administration.
Top coronavirus vaccine maker Moderna (NASDAQ: MRNA) used to be one of the stock market's stars. Sure, Moderna continues to bring in billions of dollars in vaccine revenue. First, let's take a step back and look at what Moderna's done so far.
Heart disease is the leading cause of death in the United States and according to the Centers for Disease Control and Prevention, "One person dies every 34 seconds in the United States from cardiovascular disease. About 697,000 people in the United States died from heart disease in 2020—that's 1 in every 5 deaths." And the stats for strokes are just as alarming. The CDC states, "In 2020, 1 in 6 deaths from cardiovascular disease was due to stroke. Every 40 seconds, someone in the United States h